The program brings together Bio‑Sourcing’s BioMilk platform, which leverages natural milk components to protect and transport biologics through the gastrointestinal tract and has already been used to produce TrastuzOral and Zerion’s solid oral‑dosage capabilities using its protein‑based Dispersome technology.

Over 36 months, the consortium will optimize an orally deliverable trastuzumab biobetter produced in goat milk and progress it through preclinical validation, with the ambition to prepare for entry into Phase I clinical studies around 2030. The total project budget is EUR 1.3 million, with Bio‑Sourcing as lead and Zerion as partner.

“I believe that our joint project holds a significant promise for improving the treatment of breast cancer patients and will further open up a plethora of additional opportunities for switching injectables to orally administered drugs. This blue stamping from EUREKA is also another recognition of our Dispersome technology and our excellent team of scientists that has relentlessly transformed great academic science into a commercially successful technology. I am grateful for that,” says Ole Wiborg, CEO of Zerion Pharma.